• Formycon cut 2026 adjusted EBITDA guidance to EUR -15 million to EUR -5 million from EUR 5 million to EUR 15 million.
• Revenue remains forecast at EUR 60 million–EUR 70 million; EBITDA at EUR 0 million–EUR 10 million, both at the lower end.
• Year-end net working capital is still expected at EUR 20 million to EUR 30 million.
• Lower FYB201 revenue expectations reduced the expected contribution from Bioeq, which is included in adjusted EBITDA.
• Non-cash impairments reflecting lower partner revenue expectations reduce net income by EUR 82 million for FYB202 and EUR 39 million for FYB201.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Formycon AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2429294_en) on November 05, 2026, and is solely responsible for the information contained therein.